CY1123623T1 - Θεραπεια νευρολογικων νοσων - Google Patents
Θεραπεια νευρολογικων νοσωνInfo
- Publication number
- CY1123623T1 CY1123623T1 CY20201101167T CY201101167T CY1123623T1 CY 1123623 T1 CY1123623 T1 CY 1123623T1 CY 20201101167 T CY20201101167 T CY 20201101167T CY 201101167 T CY201101167 T CY 201101167T CY 1123623 T1 CY1123623 T1 CY 1123623T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- neurological diseases
- gip
- glp
- disease
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
Abstract
Μορφές και υλοποιήσεις της παρούσας εφεύρεσης αφορούν τη θεραπεία νευρολογικών διαταραχών όπως παραδείγματος χάριν, της νόσου του Αλτσχάιμερ και της νόσου του Πάρκινσον. Ιδιαίτερα, συγκεκριμένες υλοποιήσεις αφορούν πεπτίδια συναγωνιστή GIP/GLP-1 για χρήση στη θεραπεία αυτών των δύο νευρολογικών διαταραχών. Στην παρούσα εφεύρεση επίσης συμπεριλαμβάνονται μεταξύ άλλων φαρμακευτικές συνθέσεις που περιλαμβάνουν τα πεπτίδια συναγωνιστή GIP/GLP-1, μαζί με μεθόδους θεραπείας τέτοιων διαταραχών όπως επίσης άλλων αντικειμένων.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1620611.2A GB201620611D0 (en) | 2016-12-05 | 2016-12-05 | Treatment of neurological diseases |
| PCT/GB2017/053655 WO2018104718A1 (en) | 2016-12-05 | 2017-12-04 | Treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123623T1 true CY1123623T1 (el) | 2022-03-24 |
Family
ID=58159786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201101167T CY1123623T1 (el) | 2016-12-05 | 2020-12-09 | Θεραπεια νευρολογικων νοσων |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11220534B2 (el) |
| EP (1) | EP3548061B1 (el) |
| JP (1) | JP7099729B2 (el) |
| KR (1) | KR102600128B1 (el) |
| CN (1) | CN110312520B (el) |
| AU (1) | AU2017371811B2 (el) |
| BR (1) | BR112019011462A2 (el) |
| CA (1) | CA3044797A1 (el) |
| CL (1) | CL2019001512A1 (el) |
| CO (1) | CO2019006979A2 (el) |
| CY (1) | CY1123623T1 (el) |
| DK (1) | DK3548061T3 (el) |
| ES (1) | ES2833408T3 (el) |
| GB (1) | GB201620611D0 (el) |
| HR (1) | HRP20201959T1 (el) |
| HU (1) | HUE052766T2 (el) |
| LT (1) | LT3548061T (el) |
| MX (1) | MX2019006495A (el) |
| PT (1) | PT3548061T (el) |
| RS (1) | RS61230B1 (el) |
| RU (1) | RU2755997C2 (el) |
| SI (1) | SI3548061T1 (el) |
| WO (1) | WO2018104718A1 (el) |
| ZA (1) | ZA201903003B (el) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| TW202140058A (zh) * | 2020-01-30 | 2021-11-01 | 美商美國禮來大藥廠 | 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途 |
| BR112023000270A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| CN114042149B (zh) * | 2021-12-03 | 2023-06-16 | 中国人民解放军空军军医大学 | D-Ala2-GIP用于制备治疗焦虑症药物的应用 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2023151594A1 (en) * | 2022-02-11 | 2023-08-17 | Hangzhou Sciwind Biosciences Co., Ltd. | A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009523129A (ja) * | 2006-01-05 | 2009-06-18 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | 神経系を標的する薬理学的物質の性質を改善することに関連する方法および組成物 |
| EP2952202B1 (en) | 2008-06-17 | 2017-10-18 | Indiana University Research and Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| JP2012505637A (ja) * | 2008-10-15 | 2012-03-08 | アンジオケム，インコーポレーテッド | Ｇｌｐ−１アゴニストのコンジュゲート及びその使用 |
| MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
| RU2607033C2 (ru) | 2010-09-28 | 2017-01-10 | Ноно Инк. | Пептиды nd2 и способы лечения неврологического заболевания |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| WO2013054110A2 (en) | 2011-10-10 | 2013-04-18 | University Of Lancaster | Compositions for binding to amyloid proteins |
| US10100097B2 (en) * | 2012-05-03 | 2018-10-16 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| EP2864351B1 (en) * | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| RS60625B1 (sr) * | 2014-05-28 | 2020-09-30 | Nono Inc | Hloridna so tat-nr2b9c |
| GB2528436A (en) * | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| US20160143920A1 (en) * | 2014-10-22 | 2016-05-26 | Morris Notelovitz | Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging |
| US20170112897A1 (en) | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| CN108473547A (zh) | 2015-10-28 | 2018-08-31 | 塔夫茨大学 | 具有改良的蛋白质分解安定性的新颖多肽，以及制备与使用该新颖多肽的方法 |
| WO2017210168A1 (en) | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Aqueously soluble and chemically stable depsi glucagon agonists |
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
-
2016
- 2016-12-05 GB GBGB1620611.2A patent/GB201620611D0/en not_active Ceased
-
2017
- 2017-12-04 US US16/466,194 patent/US11220534B2/en active Active
- 2017-12-04 CA CA3044797A patent/CA3044797A1/en active Pending
- 2017-12-04 ES ES17811693T patent/ES2833408T3/es active Active
- 2017-12-04 JP JP2019529926A patent/JP7099729B2/ja active Active
- 2017-12-04 RS RS20201491A patent/RS61230B1/sr unknown
- 2017-12-04 CN CN201780075565.8A patent/CN110312520B/zh active Active
- 2017-12-04 AU AU2017371811A patent/AU2017371811B2/en active Active
- 2017-12-04 EP EP17811693.5A patent/EP3548061B1/en active Active
- 2017-12-04 HU HUE17811693A patent/HUE052766T2/hu unknown
- 2017-12-04 SI SI201730543T patent/SI3548061T1/sl unknown
- 2017-12-04 LT LTEP17811693.5T patent/LT3548061T/lt unknown
- 2017-12-04 BR BR112019011462A patent/BR112019011462A2/pt unknown
- 2017-12-04 PT PT178116935T patent/PT3548061T/pt unknown
- 2017-12-04 DK DK17811693.5T patent/DK3548061T3/da active
- 2017-12-04 MX MX2019006495A patent/MX2019006495A/es unknown
- 2017-12-04 KR KR1020197015601A patent/KR102600128B1/ko active IP Right Grant
- 2017-12-04 RU RU2019118165A patent/RU2755997C2/ru active
- 2017-12-04 WO PCT/GB2017/053655 patent/WO2018104718A1/en active Application Filing
-
2019
- 2019-05-14 ZA ZA2019/03003A patent/ZA201903003B/en unknown
- 2019-06-04 CL CL2019001512A patent/CL2019001512A1/es unknown
- 2019-06-27 CO CONC2019/0006979A patent/CO2019006979A2/es unknown
-
2020
- 2020-12-07 HR HRP20201959TT patent/HRP20201959T1/hr unknown
- 2020-12-09 CY CY20201101167T patent/CY1123623T1/el unknown
-
2021
- 2021-10-13 US US17/500,430 patent/US11851468B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123623T1 (el) | Θεραπεια νευρολογικων νοσων | |
| CO2018012482A2 (es) | Formulaciones de un inhibidor de lsd1 | |
| PE20200494A1 (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson | |
| CO2018004564A2 (es) | Genes de ataxia de friedreich modificados y vectores para terapia génica | |
| CY1122265T1 (el) | Αντισωματα εναντι ταυ και χρησεις αυτων | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| CY1124704T1 (el) | Παραγωγα sobetirome | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
| CO2019002889A2 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
| CY1122374T1 (el) | Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων |